Pub Date : 2026-03-01Epub Date: 2026-02-18DOI: 10.1016/j.dsx.2026.103389
Amerta Ghosh , Anoop Misra
{"title":"Abdominal obesity (Waist Circumference/Waist Circumference-to-Height Ratio) as a new vital sign in Asian Indians: The most dangerous fat we rarely measure","authors":"Amerta Ghosh , Anoop Misra","doi":"10.1016/j.dsx.2026.103389","DOIUrl":"10.1016/j.dsx.2026.103389","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 3","pages":"Article 103389"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-05DOI: 10.1016/j.dsx.2026.103399
Andrew P. Hills , Fadiah Alkhattabi , Reem Alahmed , Saleh Ali Alessy , Sisitha Jayasinghe , Sadeem Aldarwesh , Rowaedh A. Bawaked , Lama Abdulla , Sawsan Albalawi , Afaf Alsagheir , Ghadi Alaskar , Severin Rakic , Predrag Zivotic , Volkan Cetinkaya , Saleh A. Alqahtani
Introduction/background
Competence in fundamental movement skills (FMS) is associated with higher physical activity levels across childhood and adolescence, influencing lifelong movement behaviours. Despite these benefits, most children globally fail to meet recommended physical activity levels from an early age and are increasingly affected by unhealthy body composition and chronic conditions such as obesity and type 2 diabetes (T2D). This article synthesises current evidence on early-life movement behaviours and interventions promoting physical activity during the first 2000 days, a critical developmental period shaping long-term health.
Materials and methods
A comprehensive search of peer-reviewed randomized controlled trials (RCTs) published between 2020 and 2025 in Medline and Scopus identified studies examining physical activity, motor skill development, and related health outcomes in children aged 0-5 years. Findings were organized into five themes: (1) movement behaviours and early health; (2) historical development of guidelines; (3) global consensus and gaps; (4) early-years interventions; and (5) emerging implications.
Results
Eighteen studies met inclusion criteria. Evidence highlighted the importance of physical activity, adequate rest, and limited sedentary behaviour for early development. Most studies focused on preschoolers, with fewer addressing infants and toddlers. Interventions were largely from high-income contexts and varied in design and measurement tools. Integrating physical literacy showed promise.
Discussion
Early movement experiences shape body composition and chronic disease risk. Focusing on the first and next 1000 days may foster lifelong healthy habits. Future work should enhance equity, diversity, and measurement consistency in interventions.
{"title":"Impact of early life exposure to active play and movement on health and wellbeing across the lifespan: A narrative review of RCTs from 2020-2025","authors":"Andrew P. Hills , Fadiah Alkhattabi , Reem Alahmed , Saleh Ali Alessy , Sisitha Jayasinghe , Sadeem Aldarwesh , Rowaedh A. Bawaked , Lama Abdulla , Sawsan Albalawi , Afaf Alsagheir , Ghadi Alaskar , Severin Rakic , Predrag Zivotic , Volkan Cetinkaya , Saleh A. Alqahtani","doi":"10.1016/j.dsx.2026.103399","DOIUrl":"10.1016/j.dsx.2026.103399","url":null,"abstract":"<div><h3>Introduction/background</h3><div>Competence in fundamental movement skills (FMS) is associated with higher physical activity levels across childhood and adolescence, influencing lifelong movement behaviours. Despite these benefits, most children globally fail to meet recommended physical activity levels from an early age and are increasingly affected by unhealthy body composition and chronic conditions such as obesity and type 2 diabetes (T2D). This article synthesises current evidence on early-life movement behaviours and interventions promoting physical activity during the first 2000 days, a critical developmental period shaping long-term health.</div></div><div><h3>Materials and methods</h3><div>A comprehensive search of peer-reviewed randomized controlled trials (RCTs) published between 2020 and 2025 in Medline and Scopus identified studies examining physical activity, motor skill development, and related health outcomes in children aged 0-5 years. Findings were organized into five themes: (1) movement behaviours and early health; (2) historical development of guidelines; (3) global consensus and gaps; (4) early-years interventions; and (5) emerging implications.</div></div><div><h3>Results</h3><div>Eighteen studies met inclusion criteria. Evidence highlighted the importance of physical activity, adequate rest, and limited sedentary behaviour for early development. Most studies focused on preschoolers, with fewer addressing infants and toddlers. Interventions were largely from high-income contexts and varied in design and measurement tools. Integrating physical literacy showed promise.</div></div><div><h3>Discussion</h3><div>Early movement experiences shape body composition and chronic disease risk. Focusing on the first and next 1000 days may foster lifelong healthy habits. Future work should enhance equity, diversity, and measurement consistency in interventions.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 3","pages":"Article 103399"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147451133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this article, we perform a systematic review and meta-analysis evaluating the effects of alpha-lipoic acid (ALA) supplementation on biochemical, clinical, inflammatory, and functional parameters in patients with diabetic polyneuropathy or diabetic peripheral neuropathy (DPN). A total of 15 articles were included, of which 12 were analyzed for outcomes. DPN is a chronic complication of Diabetes Mellitus (DM) characterized by symptoms, such as pain, sensory disturbances, and reduced quality of life. Currently, there is no definitive cure. Management focuses on controlling blood glucose and alleviating symptoms through pharmacological and non-pharmacological therapies. The aim of this study is to analyze the evidence regarding the efficacy of alpha-lipoic acid (ALA) supplementation in the management of DPN.
Results
A systematic search across multiple databases was conducted using keywords, such as “diabetes mellitus,” “diabetes mellitus type I,” “diabetes mellitus type II,” “alpha-lipoic acid,” and “ALA supplementation.” A total of 15 studies met the inclusion criteria. Of the 23 outcomes analyzed, 19 showed significant differences in favor of alpha-lipoic acid (ALA) supplementation at different doses versus a placebo or other treatments. Notable improvements were observed in Total Symptom Score (TSS) paresthesia (SMD = −1.04; 95 % CI = −1.24 to −0.84; p < 0.00001), TSS numbness (SMD = −0.23; 95 % CI = −0.44 to −0.01; p = 0.04), and the Hamburg Pain Adjective List (HPAL) (SMD = −1.00; 95 % CI = −1.15 to −0.85; p < 0.00001), among others. These improvements were particularly evident for symptoms, such as paresthesia, numbness, and burning sensations, especially at a dose of 600 mg/day. In contrast, four of the outcomes HbA1c, nitric oxide levels, sural sensory nerve action potential, and peroneal motor nerve conduction velocity showed no significant changes.
Conclusion
The evidence suggests that ALA, especially at 600 mg/day, is a safe and potentially effective adjunct therapy for symptom management in DPN, although its impact on nerve conduction and long-term glycemic control remains inconclusive.
在这篇文章中,我们进行了一项系统回顾和荟萃分析,评估了补充α -硫辛酸(ALA)对糖尿病多发性神经病变或糖尿病周围神经病变(DPN)患者的生化、临床、炎症和功能参数的影响。共纳入15篇文章,其中12篇对结果进行分析。DPN是糖尿病(DM)的一种慢性并发症,以疼痛、感觉障碍和生活质量下降等症状为特征。目前,尚无确切的治疗方法。治疗的重点是通过药物和非药物治疗控制血糖和减轻症状。本研究的目的是分析关于α -硫辛酸(ALA)补充治疗DPN疗效的证据。结果以“diabetes mellitus”、“diabetes mellitus type I”、“diabetes mellitus type II”、“α -硫辛酸”、“ALA supplement”等关键词对多个数据库进行了系统检索。共有15项研究符合纳入标准。在分析的23个结果中,有19个显示不同剂量的α -硫辛酸(ALA)补充剂与安慰剂或其他治疗相比有显著差异。在总症状评分(TSS)感觉异常(SMD = - 1.04; 95% CI = - 1.24至- 0.84;p < 0.00001)、TSS麻木(SMD = - 0.23; 95% CI = - 0.44至- 0.01;p = 0.04)和汉堡疼痛形容词表(HPAL) (SMD = - 1.00; 95% CI = - 1.15至- 0.85;p < 0.00001)等方面均有显著改善。这些改善对感觉异常、麻木和烧灼感等症状尤其明显,特别是在600毫克/天的剂量下。相比之下,糖化血红蛋白、一氧化氮水平、腓肠感觉神经动作电位、腓运动神经传导速度等4项指标无明显变化。结论尽管ALA对神经传导和长期血糖控制的影响尚不明确,但证据表明ALA,特别是600 mg/天,是一种安全且潜在有效的DPN症状管理辅助治疗。
{"title":"Effectiveness of alpha lipoic acid supplementation on biochemical, clinical, and inflammatory parameters in patients with diabetic polyneuropathy: A systematic review and meta-analysis","authors":"Ayline Vergara Salinas , Trinidad Meneses Caroca , Fernanda Peña Santibáñez , Javiera Rojo González , Michelle López-Chaparro , Marisol Barahona-Vásquez , Jessica Paola Loaiza-Giraldo , Consuelo Gómez-Valdovinos , Juan José Valenzuela-Fuenzalida , Pablo Nova-Baeza , Mathias Orellana-Donoso , Alejandro Bruna-Mejias , Gloria Cifuentes-Suazo , Gustavo Oyanedel-Amaro , Juan Sanchis-Gimeno , Guinevere Granite , Felipe Araya-Quintanilla","doi":"10.1016/j.dsx.2026.103374","DOIUrl":"10.1016/j.dsx.2026.103374","url":null,"abstract":"<div><h3>Introduction</h3><div>In this article, we perform a systematic review and meta-analysis evaluating the effects of alpha-lipoic acid (ALA) supplementation on biochemical, clinical, inflammatory, and functional parameters in patients with diabetic polyneuropathy or diabetic peripheral neuropathy (DPN). A total of 15 articles were included, of which 12 were analyzed for outcomes. DPN is a chronic complication of Diabetes Mellitus (DM) characterized by symptoms, such as pain, sensory disturbances, and reduced quality of life. Currently, there is no definitive cure. Management focuses on controlling blood glucose and alleviating symptoms through pharmacological and non-pharmacological therapies. The aim of this study is to analyze the evidence regarding the efficacy of alpha-lipoic acid (ALA) supplementation in the management of DPN.</div></div><div><h3>Results</h3><div>A systematic search across multiple databases was conducted using keywords, such as “diabetes mellitus,” “diabetes mellitus type I,” “diabetes mellitus type II,” “alpha-lipoic acid,” and “ALA supplementation.” A total of 15 studies met the inclusion criteria. Of the 23 outcomes analyzed, 19 showed significant differences in favor of alpha-lipoic acid (ALA) supplementation at different doses versus a placebo or other treatments. Notable improvements were observed in Total Symptom Score (TSS) paresthesia (SMD = −1.04; 95 % CI = −1.24 to −0.84; p < 0.00001), TSS numbness (SMD = −0.23; 95 % CI = −0.44 to −0.01; p = 0.04), and the Hamburg Pain Adjective List (HPAL) (SMD = −1.00; 95 % CI = −1.15 to −0.85; p < 0.00001), among others. These improvements were particularly evident for symptoms, such as paresthesia, numbness, and burning sensations, especially at a dose of 600 mg/day. In contrast, four of the outcomes HbA1c, nitric oxide levels, sural sensory nerve action potential, and peroneal motor nerve conduction velocity showed no significant changes.</div></div><div><h3>Conclusion</h3><div>The evidence suggests that ALA, especially at 600 mg/day, is a safe and potentially effective adjunct therapy for symptom management in DPN, although its impact on nerve conduction and long-term glycemic control remains inconclusive.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103374"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146081425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Blood-based non-invasive tests (NITs) in patients with T2DM/MASLD help in assessing the stage of hepatic fibrosis, but there is sparse data in the Indian population.
Methods
Fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS) were calculated for all individuals with T2DM with MASLD and compared to liver stiffness measurement (LSM) values obtained by vibration-controlled transient elastography (VCTE) with cut-offs of ≥9.7 kPa (rule-in cut-off for advanced fibrosis) and <6 kPa (as a rule-out cut-off for significant fibrosis).
Results
The prospective study included 789 patients (238 females) with T2DM and MASLD, aged 53.3 ± 10.3 years. The LSM values were ≥9.7 in 102 (12.9%). Results for the whole group were as follows: The optimal rule-in cut-off for FIB-4 was 1.68 (AUROC 0.69, 95% CI 0.637–0.746, sensitivity 64.7%, specificity 65.2%). The optimal rule-in cut-off of NFS for advanced fibrosis was −0.389 (AUROC 0.619, 95% CI 0.560 to 0.678, sensitivity 61.8%, specificity 57.4%). Rule-out cut-offs also had poor AUROCs (0.586 for FIB-4 and 0.570 for NFS). The diagnostic accuracy of the earlier suggested rule-in (for advanced fibrosis) cut-offs of FIB-4 (>2.67) was 81.3% (sensitivity 22.1%, specificity 92.2%). The diagnostic accuracy of NFS (>0.675) for advanced fibrosis was 79.4% (sensitivity 21.3% and specificity 90.1%). The diagnostic accuracy of the rule-out cut-offs was 52.7% for FIB-4 (at value < 1.3) and 53.8% for NFS (at value < -1.455).
Conclusion
The performance of FIB-4 and NFS to predict or rule out advanced fibrosis was poor in Indian patients with type 2 diabetes mellitus and MASLD.
{"title":"Performance of fibrosis-4 and NAFLD fibrosis score for screening liver fibrosis in Indian individuals with type 2 diabetes: a prospective cross-sectional study","authors":"Narendra Singh Choudhary , Mohammad Shafi Kuchay , Swapnil Dhampalwar , Kunwar Ashish Singh , Manish Kumar Singh , Gargi Singh , Neeraj Saraf , Ajay Duseja","doi":"10.1016/j.dsx.2026.103380","DOIUrl":"10.1016/j.dsx.2026.103380","url":null,"abstract":"<div><h3>Background</h3><div>Blood-based non-invasive tests (NITs) in patients with T2DM/MASLD help in assessing the stage of hepatic fibrosis, but there is sparse data in the Indian population.</div></div><div><h3>Methods</h3><div>Fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS) were calculated for all individuals with T2DM with MASLD and compared to liver stiffness measurement (LSM) values obtained by vibration-controlled transient elastography (VCTE) with cut-offs of ≥9.7 kPa (rule-in cut-off for advanced fibrosis) and <6 kPa (as a rule-out cut-off for significant fibrosis).</div></div><div><h3>Results</h3><div>The prospective study included 789 patients (238 females) with T2DM and MASLD, aged 53.3 ± 10.3 years. The LSM values were ≥9.7 in 102 (12.9%). Results for the whole group were as follows: The optimal rule-in cut-off for FIB-4 was 1.68 (AUROC 0.69, 95% CI 0.637–0.746, sensitivity 64.7%, specificity 65.2%). The optimal rule-in cut-off of NFS for advanced fibrosis was −0.389 (AUROC 0.619, 95% CI 0.560 to 0.678, sensitivity 61.8%, specificity 57.4%). Rule-out cut-offs also had poor AUROCs (0.586 for FIB-4 and 0.570 for NFS). The diagnostic accuracy of the earlier suggested rule-in (for advanced fibrosis) cut-offs of FIB-4 (>2.67) was 81.3% (sensitivity 22.1%, specificity 92.2%). The diagnostic accuracy of NFS (>0.675) for advanced fibrosis was 79.4% (sensitivity 21.3% and specificity 90.1%). The diagnostic accuracy of the rule-out cut-offs was 52.7% for FIB-4 (at value < 1.3) and 53.8% for NFS (at value < -1.455).</div></div><div><h3>Conclusion</h3><div>The performance of FIB-4 and NFS to predict or rule out advanced fibrosis was poor in Indian patients with type 2 diabetes mellitus and MASLD.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103380"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-31DOI: 10.1016/j.dsx.2026.103378
Bishwajit Bhowmik , Tasnima Siddiquee , Nayla Cdv. Moreira , Amit Gupta , Banshi Saboo , A.K.A. Khan , Sameer Pathan , Phil Riley , Abhimanyu S. Chauhan
Aims
To examine global stakeholder perspectives on the availability, affordability, and access barriers to insulin and oral hypoglycaemic agents (OHAs), based on a cross-sectional survey of International Diabetes Federation (IDF) member associations.
Methods
A mixed-methods online survey was conducted among designated informants from 86 IDF member associations across 131 responses. The questionnaire covered medicine availability, reimbursement mechanisms, affordability, and access constraints. Quantitative data were analysed descriptively, and open-ended responses were thematically analysed. In cases of multiple responses from the same country, all were included to capture diverse perspectives.
Results
Insulin analogues were reported as available in 68.8% of settings, with full reimbursement in 63.5%. Biguanides and sulfonylureas were the most available OHAs. Major access barriers included high out-of-pocket costs, limited insurance coverage, supply disruptions, and insufficient patient education. Regional representation was uneven, with over-representation from South and Central America and under-representation from South-East Asia; thus, subgroup comparisons should be interpreted with caution.
Conclusions
Substantial perceived disparities in access to diabetes medicines persist across countries, particularly in low- and lower-middle-income settings. These findings reinforce the urgent need for improved financing, strengthened supply chains, and integrated patient-centred strategies. This study contributes to the global evidence base by providing a contemporary, policy-relevant snapshot of diabetes medicine access challenges in 2024–2025, supporting national and international efforts to close equity gaps.
{"title":"Global assessment of insulin and oral hypoglycaemic agent accessibility and affordability: A cross-sectional survey of international diabetes federation member countries","authors":"Bishwajit Bhowmik , Tasnima Siddiquee , Nayla Cdv. Moreira , Amit Gupta , Banshi Saboo , A.K.A. Khan , Sameer Pathan , Phil Riley , Abhimanyu S. Chauhan","doi":"10.1016/j.dsx.2026.103378","DOIUrl":"10.1016/j.dsx.2026.103378","url":null,"abstract":"<div><h3>Aims</h3><div>To examine global stakeholder perspectives on the availability, affordability, and access barriers to insulin and oral hypoglycaemic agents (OHAs), based on a cross-sectional survey of International Diabetes Federation (IDF) member associations.</div></div><div><h3>Methods</h3><div>A mixed-methods online survey was conducted among designated informants from 86 IDF member associations across 131 responses. The questionnaire covered medicine availability, reimbursement mechanisms, affordability, and access constraints. Quantitative data were analysed descriptively, and open-ended responses were thematically analysed. In cases of multiple responses from the same country, all were included to capture diverse perspectives.</div></div><div><h3>Results</h3><div>Insulin analogues were reported as available in 68.8% of settings, with full reimbursement in 63.5%. Biguanides and sulfonylureas were the most available OHAs. Major access barriers included high out-of-pocket costs, limited insurance coverage, supply disruptions, and insufficient patient education. Regional representation was uneven, with over-representation from South and Central America and under-representation from South-East Asia; thus, subgroup comparisons should be interpreted with caution.</div></div><div><h3>Conclusions</h3><div>Substantial perceived disparities in access to diabetes medicines persist across countries, particularly in low- and lower-middle-income settings. These findings reinforce the urgent need for improved financing, strengthened supply chains, and integrated patient-centred strategies. This study contributes to the global evidence base by providing a contemporary, policy-relevant snapshot of diabetes medicine access challenges in 2024–2025, supporting national and international efforts to close equity gaps.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103378"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-20DOI: 10.1016/j.dsx.2026.103390
Ningjian Wang , Anoop Misra
{"title":"Highlights of the current issue","authors":"Ningjian Wang , Anoop Misra","doi":"10.1016/j.dsx.2026.103390","DOIUrl":"10.1016/j.dsx.2026.103390","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103390"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147422264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-29DOI: 10.1016/j.dsx.2026.103379
Melony Fortuin-de Smidt , Olov Rolandsson , Simon J. Griffin , Patrik Wennberg
Aim
We assessed the performance of non-invasive risk prediction models to predict 10-year incident type 2 diabetes in a large Swedish cohort.
Methods
Using the Västerbotten Intervention Programme (VIP) cohort, which includes serial oral glucose tolerance tests (OGTTs), we assessed discrimination (concordance (c)-statistic) and calibration (expected-to-observed probability ratio, integrated calibration index, calibration slope and plots) before and after recalibration in twelve non-invasive models. Incident diabetes cases were determined by an OGTT at a 10-year follow-up visit or through previously validated register-based cases.
Results
Among 91708 VIP participants, the 10-year diabetes incidence was 2.8 %. Most models had acceptable discrimination (c-statistic ≥0.70 and < 0.80). Discrimination was better in women and persons <50 years old. Eight models overestimated and four models underestimated mean absolute risk. Recalibration improved miscalibration in all models. Overall, the Framingham Personal and QDScore models’ predictions were most accurate but the Framingham model included more easily obtainable variables. Most models overestimated risk in older people while no consistent pattern was observed across sexes.
Conclusion
All models required recalibration to improve prediction accuracy. The Framingham personal model is recommended for risk predictions and will be the easiest to implement.
{"title":"Assessment of the performance of non-invasive risk models to predict incident type 2 diabetes in a Swedish population – Västerbotten Intervention Programme","authors":"Melony Fortuin-de Smidt , Olov Rolandsson , Simon J. Griffin , Patrik Wennberg","doi":"10.1016/j.dsx.2026.103379","DOIUrl":"10.1016/j.dsx.2026.103379","url":null,"abstract":"<div><h3>Aim</h3><div>We assessed the performance of non-invasive risk prediction models to predict 10-year incident type 2 diabetes in a large Swedish cohort.</div></div><div><h3>Methods</h3><div>Using the Västerbotten Intervention Programme (VIP) cohort, which includes serial oral glucose tolerance tests (OGTTs), we assessed discrimination (concordance (c)-statistic) and calibration (expected-to-observed probability ratio, integrated calibration index, calibration slope and plots) before and after recalibration in twelve non-invasive models. Incident diabetes cases were determined by an OGTT at a 10-year follow-up visit or through previously validated register-based cases.</div></div><div><h3>Results</h3><div>Among 91708 VIP participants, the 10-year diabetes incidence was 2.8 %. Most models had acceptable discrimination (c-statistic ≥0.70 and < 0.80). Discrimination was better in women and persons <50 years old. Eight models overestimated and four models underestimated mean absolute risk. Recalibration improved miscalibration in all models. Overall, the Framingham Personal and QDScore models’ predictions were most accurate but the Framingham model included more easily obtainable variables. Most models overestimated risk in older people while no consistent pattern was observed across sexes.</div></div><div><h3>Conclusion</h3><div>All models required recalibration to improve prediction accuracy. The Framingham personal model is recommended for risk predictions and will be the easiest to implement.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103379"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-03DOI: 10.1016/j.dsx.2026.103381
Sarah Hassen , Cameron Razieh , Lauren O'Mahoney , Thomas J. Wilkinson , Aleksandra Gawlik-Lipinski , Shukrat O. Salisu-Olatunji , Elizabeth Hickman , Monica Kundu , Kamlesh Khunti , Clare L. Gillies
Background and aims
There is a high prevalence of long-term conditions (LTCs) among people with type 2 diabetes (T2D). This umbrella review synthesises and collates the existing evidence.
Methods
This review was registered in PROSPERO (CRD42024490470) and follows the Joanna Briggs Institute guidelines (JBI) for umbrella reviews. Comprehensive searches of Ovid Medline, Ovid Embase, Cochrane, and CINAHL databases were conducted. Systematic reviews of observational studies on cardiometabolic and renal LTCs in T2D were included. Quality was assessed using the JBI Critical Appraisal Checklist for systematic reviews, and study results were narratively synthesised.
Results
Out of 10,721 records, 20 systematic reviews (15 with meta-analyses) were included, comprising 675 primary studies. The most commonly reported cardiometabolic condition in T2D was cardiovascular disease, with a pooled prevalence ranging from 13·0% (95% CI: 11·0,15·0) to 46·0% (39·0, 54·0), followed by heart failure with the highest pooled prevalence reported as 25·0% (21·0, 28·0). For renal conditions in T2D, the overall pooled prevalence for nephropathy ranged from 4·2% (3·2, 5·3) to 38·0% (14·0, 63·0), while chronic kidney disease reported prevalence ranged from 18·2% (15·1, 21·4) to 35·5% (25·9, 45·5). The prevalence of these conditions varied by sex and income status, with higher rates observed in males and low-income and middle-income countries.
Conclusion
This review highlights the significant prevalence of cardiometabolic and renal LTCs in T2D, highlighting the need for targeted and holistic management approaches to address these comorbidities effectively.
{"title":"The prevalence of cardiometabolic and renal long-term conditions in individuals with type 2 diabetes mellitus: a global umbrella review","authors":"Sarah Hassen , Cameron Razieh , Lauren O'Mahoney , Thomas J. Wilkinson , Aleksandra Gawlik-Lipinski , Shukrat O. Salisu-Olatunji , Elizabeth Hickman , Monica Kundu , Kamlesh Khunti , Clare L. Gillies","doi":"10.1016/j.dsx.2026.103381","DOIUrl":"10.1016/j.dsx.2026.103381","url":null,"abstract":"<div><h3>Background and aims</h3><div>There is a high prevalence of long-term conditions (LTCs) among people with type 2 diabetes (T2D). This umbrella review synthesises and collates the existing evidence.</div></div><div><h3>Methods</h3><div>This review was registered in PROSPERO (CRD42024490470) and follows the Joanna Briggs Institute guidelines (JBI) for umbrella reviews. Comprehensive searches of Ovid Medline, Ovid Embase, Cochrane, and CINAHL databases were conducted. Systematic reviews of observational studies on cardiometabolic and renal LTCs in T2D were included. Quality was assessed using the JBI Critical Appraisal Checklist for systematic reviews, and study results were narratively synthesised.</div></div><div><h3>Results</h3><div>Out of 10,721 records, 20 systematic reviews (15 with meta-analyses) were included, comprising 675 primary studies. The most commonly reported cardiometabolic condition in T2D was cardiovascular disease, with a pooled prevalence ranging from 13·0% (95% CI: 11·0,15·0) to 46·0% (39·0, 54·0), followed by heart failure with the highest pooled prevalence reported as 25·0% (21·0, 28·0). For renal conditions in T2D, the overall pooled prevalence for nephropathy ranged from 4·2% (3·2, 5·3) to 38·0% (14·0, 63·0), while chronic kidney disease reported prevalence ranged from 18·2% (15·1, 21·4) to 35·5% (25·9, 45·5). The prevalence of these conditions varied by sex and income status, with higher rates observed in males and low-income and middle-income countries.</div></div><div><h3>Conclusion</h3><div>This review highlights the significant prevalence of cardiometabolic and renal LTCs in T2D, highlighting the need for targeted and holistic management approaches to address these comorbidities effectively.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103381"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-13DOI: 10.1016/j.dsx.2026.103376
S. Mackie , T. Wallace , J. Heath
Background
There is limited understanding of the impact of glucose monitoring technologies on relationships with food and eating behaviours for those with type 2 diabetes mellitus (T2DM).
Aims
With previous reviews focused on T2DM treatment burden and self-management, this review aims to enhance understanding of the impact of flash or continuous glucose monitoring (FGM/CGM) on users’ eating behaviours and relationships with food as this can inform important recommendations for CGM use amongst those with T2DM.
Method
A systematic search was conducted across four databases: Scopus, Medline, CINAHL and PubMed, from October-November 2024, following PRISMA guidelines. Studies were quality appraised and qualitative data was synthesized using thematic synthesis.
Findings
Thirteen studies met inclusion criteria and their findings were included in the synthesis. The review revealed that F/CGM enhanced participants’ nutritional awareness, supported personalised dietary experimentation, and fostered intentional eating behaviours. However, data overload and emotional burden were also reported, with some users experiencing restrictive or distressing impacts on their relationship with food. These insights inform practical recommendations for CGM implementation with those with T2DM.
Conclusion
Further research should aim to identify factors that contribute to successful adaptation to CGM and explore the long-term effects of CGM use on food relationships.
{"title":"The impact of glucose monitoring devices on relationships with food and eating behaviour for people with type 2 diabetes mellitus: A review of the literature","authors":"S. Mackie , T. Wallace , J. Heath","doi":"10.1016/j.dsx.2026.103376","DOIUrl":"10.1016/j.dsx.2026.103376","url":null,"abstract":"<div><h3>Background</h3><div>There is limited understanding of the impact of glucose monitoring technologies on relationships with food and eating behaviours for those with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Aims</h3><div>With previous reviews focused on T2DM treatment burden and self-management, this review aims to enhance understanding of the impact of flash or continuous glucose monitoring (FGM/CGM) on users’ eating behaviours and relationships with food as this can inform important recommendations for CGM use amongst those with T2DM.</div></div><div><h3>Method</h3><div>A systematic search was conducted across four databases: Scopus, Medline, CINAHL and PubMed, from October-November 2024, following PRISMA guidelines. Studies were quality appraised and qualitative data was synthesized using thematic synthesis.</div></div><div><h3>Findings</h3><div>Thirteen studies met inclusion criteria and their findings were included in the synthesis. The review revealed that F/CGM enhanced participants’ nutritional awareness, supported personalised dietary experimentation, and fostered intentional eating behaviours. However, data overload and emotional burden were also reported, with some users experiencing restrictive or distressing impacts on their relationship with food. These insights inform practical recommendations for CGM implementation with those with T2DM.</div></div><div><h3>Conclusion</h3><div>Further research should aim to identify factors that contribute to successful adaptation to CGM and explore the long-term effects of CGM use on food relationships.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103376"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146260554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To review the role of lower-body skeletal muscle non-weight-bearing simple resistance activities (SRAs), soleus push-ups (SPUs), and stretching exercises (SEs) in improving glycemic control and metabolic/circulatory outcomes in those individuals who cannot do weight-bearing aerobic exercises due to musculoskeletal, cardiorespiratory and other reasons.
Research design and methods
We conducted a narrative review of randomized controlled trials, prospective cohorts, and pilot interventions identified through searches of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, EBSCO, and ScienceDirect. We examined non-weight-bearing SRAs, SPUs, and SEs, focusing on pathophysiological mechanisms and clinical outcomes.
Results
Moderate lower-body strength is associated with 32–35% lower type 2 diabetes (T2D) risk (HR: 0.68, 95% CI: 0.49–0.94). Interrupting prolonged sitting with 3-min SRAs every 30 min reduces insulin response by 26%. SPUs—sustained, seated plantarflexion contractions—reduce postprandial glucose by 39–52% and insulin response by 60% during oral glucose tolerance tests. Passive SE for 40 min acutely lowered blood glucose by 24–28 mg/dL, chronically improves femoral blood flow by 30% and flow-mediated dilation by 25%. Benefits are likely mediated through AMPK-dependent GLUT4 translocation, myokine secretion, and improved endothelial function.
Conclusions
Lower-body SRAs, SPUs, and SEs are simple interventions that can be performed while seated and have the potential to significantly improve glucose regulation, insulin sensitivity, and vascular function in populations unable to engage in traditional weight-bearing aerobic exercise. Integration into clinical practice could provide cost-effective tools for the prevention and management of T2D. Finally, the effects of these exercises should be evaluated in long-term studies to determine their impact on glycaemic control and cardiovascular protection.
目的:探讨下半身骨骼肌非负重简单阻力运动(sra)、比目鱼俯卧撑(SPUs)和拉伸运动(SEs)对因肌肉骨骼、心肺等原因不能进行负重有氧运动的患者血糖控制和代谢/循环结局的改善作用。研究设计和方法:我们对通过PubMed/MEDLINE、Scopus、Web of Science、Cochrane Library、EBSCO和ScienceDirect检索到的随机对照试验、前瞻性队列和试点干预措施进行了叙述性回顾。我们检查了非负重sra、spu和se,重点关注病理生理机制和临床结果。结果:适度的下半身力量与2型糖尿病(T2D)风险降低32-35%相关(HR: 0.68, 95% CI: 0.49-0.94)。中断长时间静坐,每30分钟进行3分钟的sra,可使胰岛素反应降低26%。在口服葡萄糖耐量试验中,spus持续的坐式跖屈收缩可使餐后血糖降低39-52%,胰岛素反应降低60%。被动SE治疗40分钟,急性降低血糖24- 28mg /dL,慢性改善股血流量30%,血流介导扩张25%。益处可能通过ampk依赖性GLUT4易位、肌因子分泌和内皮功能改善介导。结论:下体sra、spu和SEs是一种简单的干预措施,可以在坐着的情况下进行,并且有可能显著改善无法进行传统负重有氧运动的人群的葡萄糖调节、胰岛素敏感性和血管功能。与临床实践相结合可以为T2D的预防和管理提供具有成本效益的工具。最后,这些运动的效果应该在长期研究中进行评估,以确定它们对血糖控制和心血管保护的影响。
{"title":"Non-weight-bearing lower-limb simple resistance activities, soleus push-ups, and muscle stretching: Impact on glycemic control and metabolic–circulatory outcomes","authors":"Raju Vaishya , Abhishek Vaish , Patinharayil Gopinathan , Anoop Misra","doi":"10.1016/j.dsx.2026.103375","DOIUrl":"10.1016/j.dsx.2026.103375","url":null,"abstract":"<div><h3>Objective</h3><div>To review the role of lower-body skeletal muscle non-weight-bearing simple resistance activities (SRAs), soleus push-ups (SPUs), and stretching exercises (SEs) in improving glycemic control and metabolic/circulatory outcomes in those individuals who cannot do weight-bearing aerobic exercises due to musculoskeletal, cardiorespiratory and other reasons.</div></div><div><h3>Research design and methods</h3><div>We conducted a narrative review of randomized controlled trials, prospective cohorts, and pilot interventions identified through searches of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, EBSCO, and ScienceDirect. We examined non-weight-bearing SRAs, SPUs, and SEs, focusing on pathophysiological mechanisms and clinical outcomes.</div></div><div><h3>Results</h3><div>Moderate lower-body strength is associated with 32–35% lower type 2 diabetes (T2D) risk (HR: 0.68, 95% CI: 0.49–0.94). Interrupting prolonged sitting with 3-min SRAs every 30 min reduces insulin response by 26%. SPUs—sustained, seated plantarflexion contractions—reduce postprandial glucose by 39–52% and insulin response by 60% during oral glucose tolerance tests. Passive SE for 40 min acutely lowered blood glucose by 24–28 mg/dL, chronically improves femoral blood flow by 30% and flow-mediated dilation by 25%. Benefits are likely mediated through AMPK-dependent GLUT4 translocation, myokine secretion, and improved endothelial function.</div></div><div><h3>Conclusions</h3><div>Lower-body SRAs, SPUs, and SEs are simple interventions that can be performed while seated and have the potential to significantly improve glucose regulation, insulin sensitivity, and vascular function in populations unable to engage in traditional weight-bearing aerobic exercise. Integration into clinical practice could provide cost-effective tools for the prevention and management of T2D. Finally, the effects of these exercises should be evaluated in long-term studies to determine their impact on glycaemic control and cardiovascular protection.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"20 2","pages":"Article 103375"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}